{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T05:43:24Z","timestamp":1793339004024,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100007075","name":"ESMO","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007075","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer","id":[{"id":"https:\/\/ror.org\/04hmn8g73","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100011218","name":"Sandoz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100011218","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer","id":[{"id":"https:\/\/ror.org\/04hmn8g73","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Boehringer Ingelheim"},{"name":"Bristol-Myers Squibb","id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"crossref"}]},{"name":"AstraZeneca"},{"DOI":"10.13039\/100009947","name":"Merck, Sharp and Dohme","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer","id":[{"id":"https:\/\/ror.org\/04hmn8g73","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bristol-Myers Squibb","id":[{"id":"https:\/\/ror.org\/00gtmwv55","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Bayer","id":[{"id":"https:\/\/ror.org\/04hmn8g73","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.annonc.2019.10.010","type":"journal-article","created":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T02:30:05Z","timestamp":1578277805000},"page":"17-29","source":"Crossref","is-referenced-by-count":334,"title":["Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"],"prefix":"10.1016","volume":"31","author":[{"given":"E.","family":"Zucca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Arcaini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Buske","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.W.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ponzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Raderer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Salar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Stamatopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Thieblemont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wotherspoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annonc.2019.10.010_bib1","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"263","article-title":"Nodal marginal zone B-cell lymphoma","author":"Campo","year":"2017"},{"key":"10.1016\/j.annonc.2019.10.010_bib2","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"223","article-title":"Splenic marginal zone lymphoma","author":"Piris","year":"2017"},{"key":"10.1016\/j.annonc.2019.10.010_bib3","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","first-page":"259","article-title":"Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","author":"Cook","year":"2017"},{"key":"10.1016\/j.annonc.2019.10.010_bib4","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/blood-2013-07-515155","article-title":"Clonal B-cell lymphocytosis exhibiting immunophenotypic features consistent with a marginal-zone origin: is this a distinct entity?","volume":"123","author":"Xochelli","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib5","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1182\/blood-2015-12-624304","article-title":"The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance","volume":"127","author":"Zucca","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1093\/annonc\/mds643","article-title":"ESMO Consensus conferences: guidelines on malignant lymphoma. Part 2: marginal zone lymphoma, mantle cell lymphoma, peripheral T-cell lymphoma","volume":"24","author":"Dreyling","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib7","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1136\/gut.2010.224949","article-title":"EGILS consensus report. Gastric extranodal marginal zone B-cell lymphoma of MALT","volume":"60","author":"Ruskone-Fourmestraux","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.annonc.2019.10.010_bib8","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1182\/blood-2002-07-2216","article-title":"Splenic marginal zone lymphoma","volume":"101","author":"Franco","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib9","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/sj.leu.2405068","article-title":"Splenic marginal zone lymphoma proposals for a revision of diagnostic, staging and therapeutic criteria","volume":"22","author":"Matutes","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2019.10.010_bib10","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1097\/PAS.0b013e318271243d","article-title":"Bone marrow histopathology in the diagnostic evaluation of splenic marginal-zone and splenic diffuse red pulp small B-cell lymphoma: a reliable substitute for spleen histopathology?","volume":"36","author":"Ponzoni","year":"2012","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.annonc.2019.10.010_bib11","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib12","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00428-015-1858-9","article-title":"The many faces of small B cell lymphomas with plasmacytic differentiation and the contribution of MYD88 testing","volume":"468","author":"Swerdlow","year":"2016","journal-title":"Virchows Arch"},{"key":"10.1016\/j.annonc.2019.10.010_bib13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3322\/caac.21330","article-title":"Clinicopathologic characteristics and treatment of marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma)","volume":"66","author":"Raderer","year":"2016","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.annonc.2019.10.010_bib14","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2002-04-1279","article-title":"Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue","volume":"101","author":"Zucca","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib15","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1136\/gut.52.6.912","article-title":"Paris staging system for primary gastrointestinal lymphomas","volume":"52","author":"Ruskone-Fourmestraux","year":"2003","journal-title":"Gut"},{"key":"10.1016\/j.annonc.2019.10.010_bib16","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1002\/cncr.25808","article-title":"Incidence of gastric involvement in patients with nongastrointestinal extranodal marginal zone lymphoma","volume":"117","author":"Mazloom","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.010_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/hon.2008","article-title":"Clinical manifestations of primary pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in Japanese population","volume":"31","author":"Ogusa","year":"2013","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S1470-2045(03)00981-1","article-title":"Splenic marginal-zone lymphoma: a distinct clinical and pathological entity","volume":"4","author":"Thieblemont","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib19","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CLM.2002.n.010","article-title":"Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients","volume":"3","author":"Thieblemont","year":"2002","journal-title":"Clin Lymphoma"},{"key":"10.1016\/j.annonc.2019.10.010_bib20","first-page":"194","article-title":"Splenic marginal zone lymphoma: current knowledge and future directions","volume":"26","author":"Thieblemont","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.annonc.2019.10.010_bib21","first-page":"92","article-title":"Nodal marginal zone B-cell lymphoma: a diagnostic and therapeutic dilemma","volume":"26","author":"Traverse-Glehen","year":"2012","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.annonc.2019.10.010_bib22","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic marginal zone lymphoma: from genetics to management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib23","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1182\/blood.V95.6.1950","article-title":"Non-MALT marginal zone B-cell lymphomas: a description of clinical presentation and outcome in 124 patients","volume":"95","author":"Berger","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1365-2141.2006.06437.x","article-title":"Primary nodal marginal zone B-cell lymphoma: clinical features and prognostic assessment of a rare disease","volume":"136","author":"Arcaini","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1182\/blood-2017-03-771915","article-title":"A\u00a0MALT lymphoma prognostic index","volume":"130","author":"Thieblemont","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib26","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1182\/blood-2005-11-4659","article-title":"Splenic marginal zone lymphoma: a prognostic model for clinical use","volume":"107","author":"Arcaini","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/bjh.12011","article-title":"Risk stratification for splenic marginal zone lymphoma based on haemoglobin concentration, platelet count, high lactate dehydrogenase level and extrahilar lymphadenopathy: development and validation on 593 cases","volume":"159","author":"Montalban","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib28","doi-asserted-by":"crossref","first-page":"929","DOI":"10.3109\/10428194.2013.818143","article-title":"Simplification of risk stratification for splenic marginal zone lymphoma: a point-based score for practical use","volume":"55","author":"Montalban","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2019.10.010_bib29","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.3109\/10428194.2014.897703","article-title":"Validation of the simplified prognostic score for splenic marginal zone lymphoma of the Splenic Marginal Zone Lymphoma Working Group","volume":"55","author":"Kalpadakis","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.annonc.2019.10.010_bib30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.beha.2017.01.002","article-title":"Clinical aspects and therapy of gastrointestinal MALT lymphoma","volume":"30","author":"Thieblemont","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib31","first-page":"1134","article-title":"MALT lymphomas: pathogenesis can drive treatment","volume":"25","author":"Bertoni","year":"2011","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.annonc.2019.10.010_bib32","doi-asserted-by":"crossref","first-page":"a1454","DOI":"10.1136\/bmj.a1454","article-title":"Treatment of Helicobacter pylori infection","volume":"337","author":"Fuccio","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.annonc.2019.10.010_bib33","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cgh.2009.07.017","article-title":"Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma","volume":"8","author":"Zullo","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.annonc.2019.10.010_bib34","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/MCG.0b013e318286ff72","article-title":"Eradication therapy in Helicobacter pylori-negative, gastric low-grade mucosa-associated lymphoid tissue lymphoma patients: a systematic review","volume":"47","author":"Zullo","year":"2013","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.annonc.2019.10.010_bib35","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1182\/blood-2013-02-486522","article-title":"Antibiotic therapy in nongastrointestinal MALT lymphoma: a review of the literature","volume":"122","author":"Kiesewetter","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib36","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1093\/annonc\/mdu166","article-title":"Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi","volume":"25","author":"Arcaini","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib37","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/annonc\/mds623","article-title":"Long-term outcome for gastric marginal zone lymphoma treated with radiotherapy: a retrospective, multi-centre, International Extranodal Lymphoma Study Group study","volume":"24","author":"Wirth","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib38","doi-asserted-by":"crossref","first-page":"3815","DOI":"10.1002\/cncr.25226","article-title":"Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy","volume":"116","author":"Goda","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.010_bib39","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib40","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ijrobp.2015.01.009","article-title":"Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","volume":"92","author":"Yahalom","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2019.10.010_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib42","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.ijrobp.2013.04.035","article-title":"Low-dose radiation therapy (2 Gy x 2) in the treatment of orbital lymphoma","volume":"86","author":"Fasola","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.annonc.2019.10.010_bib43","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/asheducation-2005.1.307","article-title":"Clinical presentation and management of marginal zone lymphomas","author":"Thieblemont","year":"2005","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"10.1016\/j.annonc.2019.10.010_bib44","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1200\/JCO.1995.13.10.2524","article-title":"Efficacy of single-agent chemotherapy in low-grade B-cell mucosa- associated lymphoid tissue lymphoma with prominent gastric expression","volume":"13","author":"Hammel","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib45","doi-asserted-by":"crossref","first-page":"3872","DOI":"10.1200\/JCO.2002.05.117","article-title":"Treatment of extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase II study","volume":"20","author":"Jager","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib46","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1200\/JCO.2016.70.6994","article-title":"Final results of the IELSG-19 randomized trial of mucosa-associated lymphoid tissue lymphoma: improved event-free and progression-free survival with rituximab plus chlorambucil versus either chlorambucil or rituximab monotherapy","volume":"35","author":"Zucca","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib47","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1182\/blood-2002-11-3496","article-title":"Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type","volume":"102","author":"Conconi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib48","first-page":"410a","article-title":"Anti-CD20 monoclonal antibody (rituximab) in gastric extranodal marginal zone (MALT) non-Hodgkins lymphoma (NHL) patients: clinical and biological results (phase II study)","volume":"102","author":"Martinelli","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib49","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1159\/000074641","article-title":"Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma","volume":"65","author":"Raderer","year":"2003","journal-title":"Oncology"},{"key":"10.1016\/j.annonc.2019.10.010_bib50","doi-asserted-by":"crossref","first-page":"e104","DOI":"10.1016\/S2352-3026(14)00021-0","article-title":"First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial","volume":"1","author":"Salar","year":"2014","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib51","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1182\/blood-2017-07-795302","article-title":"Long-term results of a phase II study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma","volume":"130","author":"Salar","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib52","doi-asserted-by":"crossref","first-page":"7515","DOI":"10.1200\/JCO.2018.36.15_suppl.7515","volume":"36","author":"Rummel","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib53","first-page":"1506","article-title":"IELSG-38: A phase II study of chlorambucil in combination with rituximab followed by maintenance therapy with subcutaneous rituximab in patients with extranodal marginal zone B-cell lymphoma of mucosa associated lymphoid tissue (MALT)","volume":"130","author":"Stathis","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib54","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1111\/j.1365-2141.2008.07486.x","article-title":"Chlorambucil versus observation after anti-Helicobacter therapy in gastric MALT lymphomas: results of the international randomised LY03 trial","volume":"144","author":"Hancock","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2016-06-720599","article-title":"A\u00a0phase 2 study of rituximab plus lenalidomide for mucosa-associated lymphoid tissue lymphoma","volume":"129","author":"Kiesewetter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib56","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1002\/cncr.24605","article-title":"Combination therapy with rituximab and intravenous or oral fludarabine in the first-line, systemic treatment of patients with extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue type","volume":"115","author":"Salar","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.010_bib57","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1111\/j.1365-2141.2009.07677.x","article-title":"A\u00a0phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas","volume":"145","author":"Brown","year":"2009","journal-title":"Br J Haematol"},{"issue":"Suppl 5","key":"10.1016\/j.annonc.2019.10.010_bib58","doi-asserted-by":"crossref","first-page":"v116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib59","doi-asserted-by":"crossref","first-page":"7050","DOI":"10.1200\/JCO.2005.04.031","article-title":"Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02\/96)","volume":"23","author":"Koch","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib60","first-page":"86","article-title":"The management of nongastric MALT lymphomas","volume":"28","author":"Zucca","year":"2014","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.annonc.2019.10.010_bib61","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/cncr.11893","article-title":"Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles","volume":"100","author":"Arcaini","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.010_bib62","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1182\/blood.V100.5.1648.h81702001648_1648_1654","article-title":"Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients","volume":"100","author":"Chacon","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1634\/theoncologist.2012-0251","article-title":"Treatment of splenic marginal zone lymphoma with rituximab monotherapy: progress report and comparison with splenectomy","volume":"18","author":"Kalpadakis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.annonc.2019.10.010_bib64","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/sj.leu.2401710","article-title":"Fludarabine: an effective treatment in patients with splenic lymphoma with villous lymphocytes","volume":"14","author":"Lefrere","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.annonc.2019.10.010_bib65","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1093\/annonc\/mdt181","article-title":"Significant efficacy of 2-chlorodeoxyadenosine \u00b1 rituximab in the treatment of splenic marginal zone lymphoma (SMZL): extended follow-up","volume":"24","author":"Cervetti","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/cncr.21931","article-title":"Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone","volume":"107","author":"Tsimberidou","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.annonc.2019.10.010_bib67","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/hon.820","article-title":"Rituximab monotherapy is highly effective in splenic marginal zone lymphoma","volume":"25","author":"Kalpadakis","year":"2007","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib68","first-page":"856","article-title":"Rituximab monotherapy for splenic marginal zone lymphoma","volume":"90","author":"Bennett","year":"2005","journal-title":"Haematologica"},{"key":"10.1016\/j.annonc.2019.10.010_bib69","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1111\/bjh.15641","article-title":"Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA\/IELSG36 study","volume":"183","author":"Iannitto","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib70","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1182\/blood-2018-02-833608","article-title":"Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance","volume":"132","author":"Kalpadakis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib71","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.beha.2016.07.004","article-title":"Treatment of splenic marginal zone lymphoma","volume":"30","author":"Kalpadakis","year":"2017","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib72","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.beha.2017.10.011","article-title":"Should rituximab replace splenectomy in the management of splenic marginal zone lymphoma?","volume":"31","author":"Kalpadakis","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib73","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1614598","article-title":"Obinutuzumab for the first-line treatment of follicular lymphoma","volume":"377","author":"Marcus","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.annonc.2019.10.010_bib74","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/hon.2437_136","article-title":"Immunochemotherapy with obinutuzumab or rituximab in a subset of patients in the randomised GALLIUM trial with previously untreated marginal zone lymphoma (MZL)","volume":"35","author":"Herold","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib75","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1182\/blood-2016-10-747345","article-title":"Targeting Bruton tyrosine kinase with ibrutinib in relapsed\/refractory marginal zone lymphoma","volume":"129","author":"Noy","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.annonc.2019.10.010_bib76","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1200\/JCO.2017.75.4648","article-title":"Phosphatidylinositol 3-kinase inhibition by copanlisib in relapsed or refractory indolent lymphoma","volume":"35","author":"Dreyling","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib77","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/bjh.12078","article-title":"Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice","volume":"160","author":"Copie-Bergman","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.annonc.2019.10.010_bib78","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1136\/gutjnl-2011-300495","article-title":"Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan","volume":"61","author":"Nakamura","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.annonc.2019.10.010_bib79","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1093\/annonc\/mdn760","article-title":"Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type","volume":"20","author":"Stathis","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib80","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1200\/JCO.2005.02.3903","article-title":"Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication","volume":"23","author":"Wundisch","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.annonc.2019.10.010_bib81","doi-asserted-by":"crossref","first-page":"2470","DOI":"10.1016\/j.ejca.2008.07.005","article-title":"Gastric MALT lymphoma: epidemiology and high adenocarcinoma risk in a nation-wide study","volume":"44","author":"Capelle","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.annonc.2019.10.010_bib82","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1053\/j.gastro.2012.06.035","article-title":"Second cancers and residual disease in patients treated for gastric mucosa-associated lymphoid tissue lymphoma by Helicobacter pylori eradication and followed for 10 years","volume":"143","author":"Wundisch","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.annonc.2019.10.010_bib83","doi-asserted-by":"crossref","first-page":"e47396","DOI":"10.1371\/journal.pone.0047396","article-title":"Overexpression of miR-142-5p and miR-155 in gastric mucosa-associated lymphoid tissue (MALT) lymphoma resistant to Helicobacter pylori eradication","volume":"7","author":"Saito","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.annonc.2019.10.010_bib84","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1086\/321805","article-title":"Summary of the guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients","volume":"33","author":"Dykewicz","year":"2001","journal-title":"Clin Infect Dis"}],"updated-by":[{"DOI":"10.1016\/j.annonc.2022.11.009","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000}}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419354651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419354651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,7,17]],"date-time":"2021-07-17T07:08:20Z","timestamp":1626505700000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419354651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":84,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0923753419354651"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2019.10.010","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]}}}